[go: up one dir, main page]

FR2866031B1 - Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale - Google Patents

Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale

Info

Publication number
FR2866031B1
FR2866031B1 FR0401364A FR0401364A FR2866031B1 FR 2866031 B1 FR2866031 B1 FR 2866031B1 FR 0401364 A FR0401364 A FR 0401364A FR 0401364 A FR0401364 A FR 0401364A FR 2866031 B1 FR2866031 B1 FR 2866031B1
Authority
FR
France
Prior art keywords
chimer
same
medicament containing
antiviral therapy
pathogenic virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0401364A
Other languages
English (en)
Other versions
FR2866031A1 (fr
Inventor
David Francois Joseph Millet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0401364A priority Critical patent/FR2866031B1/fr
Publication of FR2866031A1 publication Critical patent/FR2866031A1/fr
Application granted granted Critical
Publication of FR2866031B1 publication Critical patent/FR2866031B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0401364A 2004-02-11 2004-02-11 Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale Expired - Lifetime FR2866031B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0401364A FR2866031B1 (fr) 2004-02-11 2004-02-11 Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0401364A FR2866031B1 (fr) 2004-02-11 2004-02-11 Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale

Publications (2)

Publication Number Publication Date
FR2866031A1 FR2866031A1 (fr) 2005-08-12
FR2866031B1 true FR2866031B1 (fr) 2012-10-19

Family

ID=34778688

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0401364A Expired - Lifetime FR2866031B1 (fr) 2004-02-11 2004-02-11 Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale

Country Status (1)

Country Link
FR (1) FR2866031B1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345716B1 (fr) * 1999-04-06 2015-01-14 Wisconsin Alumni Research Foundation Virus de la grippe recombinant pour vaccins et thérapie génétique
DE122008000057I1 (de) * 1999-07-14 2009-04-09 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren

Also Published As

Publication number Publication date
FR2866031A1 (fr) 2005-08-12

Similar Documents

Publication Publication Date Title
DE602004018299D1 (de) Medizinprodukt mit therapeutischen mitteln
EE200400059A (et) Diarüültsükloalküülderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
PT1500654E (pt) Derivados de benzoxazinona, sua preparacao e utilizacao como medicamentos
DE60209779D1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DK1542748T3 (da) Engangssprøjte
MA28512B1 (fr) Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
IS7564A (is) Lyfjablanda með breytta losun
EE04236B1 (et) Bensimidasoolid, nende valmistamine ja kasutamineravimitena
EE200300193A (et) Asendatud bensimidasoolid, nende kasutamine ja ravim
DE60305037D1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
DE50308640D1 (de) Veterinärmedizinische spritze
AU2003302749A8 (en) Crosslinkable, photoactive polymers and their use
ITMI20030511A1 (it) Dispositivo per la cura dei capelli dotato di casco.
DK1567137T3 (da) Anvendelse af resveratrol til fremstilling af et medikament, der er anvendeligt til behandling af influenzavirusinfektioner
EP1750693A4 (fr) Medicaments et promedicaments oculoselectifs
RU2002107079A (ru) Вещество, обладающее седативным действием
FR2866031B1 (fr) Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
FR2820311B3 (fr) Distributeur de medicament portatif
IL173004A0 (en) Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments
FI20021126A0 (fi) Antimikrobinen prepreg, komposiitti ja niiden käyttö
NO20002242D0 (no) Pustende, absorberende engangsartikkel
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
MA27172A1 (fr) 3-phenyl-5-alcoxy-1,3,4-oxdiazol-2-ones substitues, ainsi que leur production et leur utilisation dans des medicaments
ITMI20021553A1 (it) Emoconcentratore in circuito ematico extracorporeo

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20